Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

CBMT17006 / A051301 / Michael Becker

Research Question:
What are the good and/or bad effects of using an oral medication, ibrutinib, along with the autologous hematopoietic stem cell transplantation (AutoHCT) versus AutoHCT alone?

Basic Study Information

Purpose:
This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Before transplant, stem cells are taken from patients and stored. Patients then receive high doses of chemotherapy to kill cancer cells and make room for healthy cells. After treatment, the stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Ibrutinib is a drug that may stop the growth of cancer cells by blocking a protein that is needed for cell growth. It is not yet known whether adding ibrutinib to chemotherapy before and after stem cell transplant may help the transplant work better in patients with relapsed or refractory diffuse large B-cell lymphoma.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02443077?term=a051301&rank=1
Study Reference #: CBMT17006

Lead Researcher (Principal Investigator)

Lead Researcher:  Michael Becker, MD

Study Contact Information

Study Coordinator: Jessica Mackowiak
Email: jessica_ellis@urmc.rochester.edu

Additional Study Details

Return to Search